SCHEMBL458899

SCHEMBL458899

CCCc1ccc(-c2ccccc2)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 3/20 0.41
RARA P10276 2/20 0.41
RARG P13631 1/20 0.41
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CHRM5 P08912 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
FFAR1 O14842 2/20 0.38
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
HTR2A P28223 1/20 0.37
SLC6A4 P31645 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27800509 0.88 RARB (0.51) RARBRARARARGHPGDKDM4E
SCHEMBL7789315 0.86 RARB (0.54) RARBRARARARGHPGDKDM4E
SCHEMBL9399833 0.85 RARB (0.48) RARBRARARARGSMN1; SMN2NPC1
SCHEMBL16377225 0.85 RARB (0.48) RARBRARARARGSMN1; SMN2NPC1
SCHEMBL17859649 0.85 FFAR1 (0.43) RARBRARARARGHPGDSMN1; SMN2
SCHEMBL29287568 0.84 RARB (0.45) RARBRARARARGMAPTFFAR1
SCHEMBL16377214 0.84 RARB (0.43) RARBRARARARGSMN1; SMN2NPC1
SCHEMBL28652298 0.82 RARB (0.50) RARBRARARARGHPGDKDM4E
SCHEMBL29068251 0.82 SMN1; SMN2 (0.42) HPGDSMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL16559804 0.82 CTSK (0.39) RARBRARARARGSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118307575-A Synthesis method of 4' -alkyl-3-fluoro-4-biphenylboronic acid 山东盛华电子新材料有限公司 2024-07-09 CN claimed
CN-118307575-A Synthesis method of 4' -alkyl-3-fluoro-4-biphenylboronic acid 山东盛华电子新材料有限公司 2024-07-09 CN disclosed
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS AG (CH) 2023-06-15 US disclosed
EP-3041842-B1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS KAROS PHARMACEUTICALS INC (US) 2019-10-23 EP disclosed
EP-2614053-A1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2013-07-17 EP disclosed
US-8252201-B1 Liquid crystalline medium Military University of Technology (PL) 2012-08-28 US disclosed
WO-2012033225-A1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA RNGTT, NSUN2, NSUN3 RARB 1989/4885RARA 1717/4885RARG 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.